Study in Participants With Early-Stage or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive to Evaluate With Trastuzumab Plus (+) Pertuzumab + Docetaxel Compared With Trastuzumab + + Docetaxel

  • Breast Cancer